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ABSTRACT
Objectives: The aim of this study was to evaluate
changes in the uptake of intrathecal baclofen (ITB)
following commissioning of this therapy by the National
Health Service (NHS) England in April 2013. The
specific objectives of this study were: (i) to explore the
gap between the need for and the actual provision of
ITB services; and (ii) to compare England figures with
other European countries with comparable data
available.
Setting: Data for ITB -related procedures were obtained
from the Hospital Episode Statistics (HES) database
from 2009/2010 to 2013/2014.
Participants: Patients receiving ITB for the
management of spasticity.
Results: The available data for implantation of ITB from
2009/2010 to 2013/2014 for the treatment of spasticity
due to varied aetiologies show that there has not been an
increase in uptake of this therapy. The estimated need for
this treatment based on the incidence and prevalence of
conditions susceptible to ITB therapy is between 4.6 and
5.7 per million population. Our analysis of the data
available from the HES database showed that the actual
number of implants is around 3.0 per million population.
The same period 2009–2014 has seen an increase in the
delivery of other neuromodulation techniques including
spinal cord stimulation, deep brain stimulation and sacral
nerve stimulation.
Conclusions: There is a considerable gap between the
need for and provision of ITB figures nationally.
Additionally, within the same area, we have observed
important differences in the ITB service delivery
between the various trusts. The reasons for this can be
multifactorial, including individual experience and
opinions, organisational structures, resource and
financial limitations. Further research analysing the
efficacy and cost-effectiveness of this treatment in the
UK might inform the development of Technology
Appraisal Guidance for ITB, potentially leading to an
improvement in service provision.
INTRODUCTION
Spasticity is a signiﬁcant health problem in a
subgroup of patients with multiple sclerosis,
spinal cord injury, cerebral palsy and trau-
matic brain injury. This ailment is charac-
terised by a motor disorder with increased
resistance to velocity-dependent passive
stretch that can be generalised or conﬁned to
a particular group of muscles. Spasticity has
been deﬁned as “disordered sensorimotor
control resulting from an upper motor
neuron (UMN) lesion, presenting as intermit-
tent or sustained involuntary activation of
muscles.”1 This syndrome can affect daily
activities including mobility and ability to
transfer, and can lead to incontinence com-
plicated by pressure sores, skin breakdown
and infection. It can also cause pain, discom-
fort, contractures, sleep disturbances and,
consequently, mood disorders.
Spasticity can be differentiated on the basis
of aetiology as spinal (eg, multiple sclerosis,
spinal cord injury, transverse myelitis) and
central spasticity (stroke, cerebral palsy, acute
brain injury). The aim of treatments for
spasticity includes improving the range of
motion, mobility, facilitating the manual
Strengths and limitations of this study
▪ This study highlights a considerable gap in the
number of intrathecal baclofen (ITB) pump
implants performed and the estimated need for
the service despite the National Health Service
England’s commissioning of ITB.
▪ Important differences in the ITB service delivery
across England have been identified and possible
reasons are provided.
▪ English ITB uptake data is compared with appro-
priate equivalent data from other European
countries.
▪ These findings are based on data extracted from
the Hospital Episodes Statistics database which
relies on hospital-coded data on procedures and
indications.
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handling of patients, preventing contractures and achiev-
ing self-care and independence.
There are various existing therapies for the manage-
ment of spasticity including physical therapy, botulinum
injections and muscle relaxants. The muscle relaxants in
common use are baclofen, tizanidine and dantrolene.
Among these, baclofen is the most commonly used.
Intrathecal drug delivery (ITDD) facilitates the direct
administration of drugs at a site of action, which allows
for the use of lower doses of the drugs, thereby reducing
their side effects while achieving maximum therapeutic
beneﬁt. Intrathecal baclofen (ITB) therapy is an effective
alternative for the management of spasticity in patients in
whom other treatment options (pharmacological agents,
non-pharmacological adjuvants) have failed to provide
adequate relief of symptoms, or for patients who derive
beneﬁt from oral or systemic medications but for whom
the side effects have become intolerable.
Since April 2013, there have been major changes in
the way services are commissioned in the National
Health Service (NHS). Primary Care Trusts, which used
to commission most NHS services and controlled 80%
of the NHS budget, have been replaced by Clinical
Commissioning Groups (CCGs). CCGs can commission
any service provider that meets NHS standards and costs
by taking into account the National Institute for Health
and Care Excellence (NICE) guidelines and the Care
Quality Commission’s (CQC) data about service provi-
ders. NHS England, formerly the NHS Commissioning
Board (NHS CB), oversees the operation and allocates
resources to CCGs.2
In April 2013, the NHS CB published a document on
clinical commissioning policy for ITB.3 It states that the
aim of the therapy is to improve passive and/or active
functioning and to prevent deformities resulting from
ﬁxed contractures. ITB therapy should not be used
simply to reduce tone and improve the range of motion.
The aim of this study is to explore the impact of NHS
England’s commissioning on the uptake of ITB for the
management of spasticity.
METHODS
Data for ITB procedural activity during the years 2009/
2010 to 2013/2014 were obtained from the Hospital
Episode Statistics (HES) database4 using the QUANTIS
system via NHiS.5 HES is a national statistical data ware-
house for England for care provided by NHS hospitals.
QUANTIS is a database of NHS and social care numer-
ical data for the UK, and NHiS is a vendor that provides
subscribed access to the QUANTIS database.
We examined OPCS-4 procedure codes A54.3
(implantation of ITDD device adjacent to spinal cord),
A54.4 (attention to ITDD device adjacent to spinal
cord), A54.5 (removal of ITDD device adjacent to spinal
cord). OPCS code 54.4 does not allow for a clear differ-
entiation between reﬁlls, catheter revision and pump
replacements.
The relevant OPCS codes were ﬁltered by indication
to ensure that only spasticity due to spinal and suprasp-
inal origin indication were included. This eliminated
any inclusion of other indications for insertion of ITDD
system such as malignant and non-malignant pain.
Insertion of ITDD system uptake is expressed per
million population across each strategic health authority
region in England.
We compared English ITB uptake data (code A54.3
only) with European countries where we were able to
source the appropriate equivalent data, that is, France,
Belgium, Germany and The Netherlands.
RESULTS
The HES data analysis between the years 2009 and 2014
show the activity trend for procedure codes A54.3, A54.4
and A54.5 (table 1). This shows minimal ﬂuctuation in
the uptake for any of these procedures except for a
small increase in A54.4. Continuing increases in proced-
ure code A54.4 are to be expected, as there are more
new implants per year than devices explanted, thereby
resulting in an increasing number of pump reﬁll
procedures.
There is considerable variation in the rate of uptake
of ITDD service between the various CCGs (ﬁgure 1).
Additionally, within the same area, there have been
important differences in the ITDD service delivery
between the various trusts.
The variation in access to ITDD therapy during 2013/
2014 is also noticeable across the different strategic area
teams indicating inequality in access to this treatment
(ﬁgure 2).
NHS England records from 2009 to 2014 suggest that
while there has been an increase in the uptake of other
neuromodulation modalities, it would appear that ITB
has not attracted as great an interest among clinicians
(ﬁgure 3).
The total number of intrathecal pumps implanted in
England for the year 2013/2014 was 394 for spasticity
and chronic pain (table 2). According to HES data, the
number of intrathecal pumps implanted in the years
2013/2014 for spasticity were 194 (3.08 per million).
Table 3 shows that the estimated incidence of ITB suit-
able cases annually is around 4.6–5.7 per million popula-
tion. There is a considerable gap between the
recommended ﬁgures and the actual implanted ﬁgures
nationally. Even with the assumption that the other
Table 1 Total number of intrathecal pump procedures
from 2009 to 2014
2009/
2010
2010/
2011
2011/
2012
2012/
2013
2013/
2014
A54.3 386 335 389 337 394
A54.4 3176 3414 3458 3729 4005
A54.5 52 63 60 58 47
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indications were all ITB pumps (276 pumps for 2013/
2014), still it would be 4.38 per million population, less
than the minimum recommended ﬁgures.
ITDD implants performed for spasticity in European
countries where data were available indicated the following
number of implants per million: Belgium—16.3, France—
1.72, The Netherlands—3.1 and Germany—13.12.7
DISCUSSION
Baclofen is a γ-aminobutyric acid (GABA) agonist pri-
marily used to treat spasticity. Spasticity results from an
imbalance of supraspinal inhibitory and excitatory
inputs, producing a state of net disinhibition of the
spinal reﬂexes. Baclofen acts by resetting this imbalance
via GABA B (GABAB) receptors. The GABAB receptor
is distributed in the central nervous system in high
density in the dorsal horn of the spinal cord, the thal-
amic nuclei, the cerebellum, the interpeduncular
nucleus and the cerebral cortex. Baclofen is well
absorbed orally, but because of its hydrophilic nature, it
crosses the blood–brain barrier poorly. It is equally dis-
tributed between spinal and supratentorial compart-
ments leading to side effects such as nausea, drowsiness,
sedation and fatigue. ITB facilitates direct infusion of
the drug at the site of action at a fraction of the oral
dose, thereby minimising the risks of adverse effects.
ITB for spasticity was ﬁrst described in 1985.8 Since
then, there have been numerous published studies dem-
onstrating its efﬁcacy in the treatment of spasticity, spasm-
related pain and improved quality of life in patients with
spasticity of spinal and supraspinal origins.9–14
Ordia et al9 conducted a prospective case series of 131
patients treated with ITB for spasticity of spinal origin.
Signiﬁcant reductions in the Ashworth and spasm
scores at a mean follow-up of 73 months (range of
2–137 months) were reported. Improvements in gait and
balance, reduction detrusor hyper-reﬂexia, reduced
need for urinary catheterisation and improved speech in
patients with oropharyngeal muscle involvement were
also observed. There were 24 catheter-related complica-
tions and 34 drug-related occurrences.
Figure 1 Number of intrathecal
drug delivery implants per million
population for 87 Clinical
Commissioning Groups (CCGs)
in 2013–2014. In total 117 CCGs
performed between 1 and 5
implants per million; 7 CCGs did
not perform any implants.
Figure 2 Number of intrathecal drug delivery implants per million population for each Area Team in 2013–2014. Where
numbers were masked for patient confidentiality (between 1 and 5 procedures), 3 was used as an estimation in order that the
rate per million could be calculated.
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A prospective multicentre ITB case series with a 3-year
follow-up in 64 patients with spasticity of spinal origin
identiﬁed a decrease in the Ashworth scale greater than
two points and a reduction in spasm score.10 These
results were sustained at 3 years. Greater improvements
were observed in patients under 25 and/or with com-
plete spinal cord injury. Although observed, improve-
ments in functional outcome were not quantiﬁed.
Drug-related or catheter-related complications occurred
in 19/64 (30%) patients.
An observational study with a follow-up ranging from
12 months to 10 years observed signiﬁcant improvements
in the Ashworth score, spasm score and functional
outcome in 18 patients with spasticity of supraspinal
origin.11 The efﬁcacy of ITB therapy in children suffer-
ing from spasticity has also been observed.12 15–17
Economic evaluations have suggested ITB to be a cost-
effective alternative when compared with other treat-
ment modalities.13 14 18 Including ITB as a ﬁrst-option
strategy in the management of function of severely
impaired patients with disabling spasticity resulted in a
higher success rate (78.7% vs 59.3%) when compared
with a range of alternative strategies, such as sequential
combinations of physical treatment, oral or focal treat-
ment, or surgery or nursing using a mathematical simu-
lation model.13 In addition, the ITB therapy model
revealed a lower medical cost (€59 391 vs €88 272) over
a 2-year time horizon, and an overall favourable cost-
effectiveness ratio (€75 204/success vs €148 822/success)
when compared with conventional medical management
without ITB. In another study, de Lissovoy et al14 used
mathematical modelling and computer simulation to
estimate the incremental cost per quality-adjusted life-
year (QALY) for identical cohorts of children treated
with ITB or alternative therapy over a 5-year time
horizon. The incremental cost-effectiveness ratio was cal-
culated to be $42 000 per QALY (approximately
£26 588), a ﬁgure considered as cost-effective, consider-
ing the willingness-to-pay threshold in the UK of
between £20 000 and £30 000 per QALY. A systematic
review evaluating the effect of continuous ITB infusion
on function and quality of life in patients with severe
spasticity concluded that ITB has a cost per QALY in the
region of £6900–£12 800.18
This study suggests that despite the available evidence
on effectiveness and cost-effectiveness, and although
NHS England has issued a policy statement on ITB,
there are still many patients who have not been able to
access this therapy. We believe this to be related to the
complexity of the set-up required to deliver the therapy
and the need for interaction between a number of spe-
cialties, including neurosurgery, pain medicine, neuror-
ehabilitation and spinal injuries, all of which may not be
present on the same hospital site. The creation of spe-
cialist centres will and should overcome this problem in
the future, although estimating the duration for the
impact of specialised centres is difﬁcult at this point. In
comparison with other Western European countries, the
UK is one of the lowest providers of ITB therapy.
However, the data are available for other European
Figure 3 Total neuromodulation
implant procedures from 2009 to
2014. DBS, deep brain
stimulation; ITB, intrathecal
baclofen; NHS, National Health
Service; SCS, spinal cord
stimulation; SNS, sacral nerve
stimulation.
Table 2 Total number of intrathecal drug delivery implants for spasticity and other indications
2009/2010 2010/2011 2011/2012 2012/2013 2013/2014
Multiple sclerosis 102 74 88 92 103
Cerebral palsy 53 58 48 55 51
Plegias 37 36 43 43 40
Cancer pain 38 28 57 37 65
Non-cancer pain 80 63 59 40 53
Other 76 76 94 70 82
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countries for only 1 year, and therefore we cannot
comment on trends. There is also a considerable vari-
ation in provision of services among various CCGs. The
number of implants performed in the North of England
commissioning region was 148 compared with 62 and 70
in the Midlands and South of England commissioning
regions during the years 2012/2013. The number of
implants cannot be explained based on population
factors; the population ﬁgures are much higher for the
South (27,830,219) than the North (15,845,124) and
Midlands (12,694,544). We can only speculate that the
differences may relate to several factors including a
number of high-volume implanting centres based in the
North of England. In addition, the variations in commis-
sioning between CCGs may be explained by the individ-
ual ITB commissioning policies of the CCG precursors
(the Primary Care Trusts) with more permissive Primary
Care Trust policies towards implant of ITB pumps in the
North than in the South or Midlands. It has previously
been observed that commissioning policies varied vastly
between Primary Care Trusts in respect to SCS commis-
sioning.19 The Right Care20 is one of the national work
streams in the DH Quality Innovation Productivity and
Prevention programme which identiﬁes unwarranted
variation in NHS treatments based on geographical
areas. One of the Right Care objectives for 2011–2012 is
to minimise this unwarranted variation and maximise
value. Value can be increased by improving quality, opti-
mising resource utilisation and ensuring that patients
receive appropriate interventions. Direction of commis-
sioning towards specialised centres may lead to an
improvement in uptake.
There may be several reasons for this inequality in or
lack of service provision. The care of patients suffering
from spasticity due to various causes is shared between
specialties and requires service coordination and man-
agement. There is a continuing shortfall of resources
and funding of rehabilitation services with ever increas-
ing demand on these services as well as lack of coordi-
nated service provision between a number of specialties.
Finally, there may be an element of reluctance to adopt
a new technology, particularly if the latter is invasive
involving a permanent implantation. This reluctance
may be due to perception of harm and perceived high
level of complications despite published articles support-
ing the safety and efﬁcacy of this treatment.21 With lack
of resources, there are ever increasing challenges in
setting up a new service and the increasing scrutiny of
cost-effectiveness.
CONCLUSION
Our study shows that there is a considerable gap in the
number of ITB pump implants performed and the esti-
mated need for the service. We also lag behind our
European counterparts in provision of the treatment,
which can potentially relieve the symptoms and improve
the quality of life in patients suffering from these
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conditions. There is a need to establish a service com-
mitment to these patients by improving our multidiscip-
linary approach, education of those who provide care
for these patients, and laying down referral pathways to
the ITB service. The clinical commissioning policy for
ITB therapy published recently can provide a pathway to
improve uptake of this service.
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